N
Nico Pfeifer
Researcher at University of Tübingen
Publications - 96
Citations - 4825
Nico Pfeifer is an academic researcher from University of Tübingen. The author has contributed to research in topics: Computer science & Antibody. The author has an hindex of 27, co-authored 84 publications receiving 3772 citations. Previous affiliations of Nico Pfeifer include Max Planck Society & Microsoft.
Papers
More filters
Journal ArticleDOI
Widespread Impact of HLA Restriction on Immune Control and Escape Pathways of HIV-1
Jonathan M. Carlson,Jennifer Listgarten,Nico Pfeifer,Vincent Y. F. Tan,Carl M. Kadie,Bruce D. Walker,Bruce D. Walker,Bruce D. Walker,Thumbi Ndung'u,Thumbi Ndung'u,Roger L. Shapiro,John Frater,Zabrina L. Brumme,Zabrina L. Brumme,Philip J. R. Goulder,Philip J. R. Goulder,David Heckerman +16 more
TL;DR: These studies confirm that differential escape is a widespread phenomenon and may be the norm when two alleles present the same epitope, and suggest that certain epitopes will lead to discordant outcomes if applied universally in a vaccine.
Journal ArticleDOI
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.
Kanika Vanshylla,Veronica Di Cristanziano,Franziska Kleipass,Felix Dewald,Philipp Schommers,Lutz Gieselmann,Henning Gruell,Maike Schlotz,Meryem S. Ercanoglu,Ricarda Stumpf,Petra Mayer,Matthias Zehner,Eva Heger,Wibke Johannis,Carola Horn,Isabelle Suárez,Norma Jung,Susanne Salomon,Kirsten Alexandra Eberhardt,Kirsten Alexandra Eberhardt,Birgit Gathof,Gerd Fätkenheuer,Nico Pfeifer,Ralf Eggeling,Max Augustin,Clara Lehmann,Florian Klein +26 more
TL;DR: In this article, the authors evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19 and found that approximately 3% of individuals demonstrated exceptional SARSCoV2 neutralization, with these "elite neutralizers" also possessing SARS CoV-1 cross-neutralizing IgG.
Journal ArticleDOI
Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1
Jonathan M. Carlson,Chanson J. Brumme,Eric Martin,Jennifer Listgarten,Mark A. Brockman,Mark A. Brockman,Anh Q. Le,Celia K. S. Chui,Laura A. Cotton,David J.H.F. Knapp,Sharon A. Riddler,Richard Haubrich,George W. Nelson,Nico Pfeifer,Charles E. DeZiel,David Heckerman,Richard Apps,Mary Carrington,Simon Mallal,Simon Mallal,P. Richard Harrigan,Mina John,Mina John,Zabrina L. Brumme,Zabrina L. Brumme +24 more
TL;DR: The authors analyzed 2,100 HLA-associated HIV-1 subtype B polymorphisms in 1,888 treatment-naive, chronically infected individuals using phylogenetically informed methods and identified characteristics of HLAassociated immune pressures that differentiate protective and non-protective alleles.
Journal ArticleDOI
Impact of pre-Adapted HIV transmission
Jonathan M. Carlson,Victor Y. Du,Nico Pfeifer,Anju Bansal,Vincent Y. F. Tan,Vincent Y. F. Tan,Karen A. Power,Chanson J. Brumme,Anat Kreimer,Anat Kreimer,Charles E. DeZiel,Nicolo Fusi,Malinda Schaefer,Mark A. Brockman,Mark A. Brockman,Jill Gilmour,Jill Gilmour,Matthew Price,Matthew Price,William Kilembe,Richard Haubrich,Mina John,Mina John,Simon Mallal,Simon Mallal,Roger L. Shapiro,John Frater,P. Richard Harrigan,Thumbi Ndung'u,Susan Allen,David Heckerman,John Sidney,Todd M. Allen,Philip J. R. Goulder,Philip J. R. Goulder,Zabrina L. Brumme,Zabrina L. Brumme,Eric Hunter,Eric Hunter,Paul A. Goepfert +39 more
TL;DR: It is demonstrated that transmission of viruses that are pre-adapted to the HLA molecules expressed in the recipient is associated with impaired immunogenicity, elevated viral load and accelerated CD4+ T cell decline.
Journal ArticleDOI
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
Stefanie A Ehrhardt,Matthias Zehner,Verena Krähling,Hadas Cohen-Dvashi,Christoph Kreer,Nadav Elad,Henning Gruell,Meryem S. Ercanoglu,Philipp Schommers,Lutz Gieselmann,Ralf Eggeling,Christine Dahlke,Christine Dahlke,Timo Wolf,Nico Pfeifer,Marylyn M. Addo,Marylyn M. Addo,Ron Diskin,Stephan Becker,Florian Klein +19 more
TL;DR: The humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial is examined by performing comprehensive single B cell and electron microscopy structure analyses, and highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials are detected.